Tisolagiline is a potent, selective, and reversible MAO-B inhibitor, which overcomes the drawbacks of existing irreversible and reversible MAO-B inhibitors.
It had shown superior medicinal effect in preclinical trials in neuroinflammation, neurodegeneration disease, mental illness and obesity indication. It also proved excellent PK and shown no SAEs or SUSARs in phase 1 clinical trial. Clinical trial for obesity and AD is on-going and other indications are under planning.